BioCentury | Oct 24, 2011
Company News

PDL BioPharma other news

...acquisition opportunities. Berger is a director at: Five Prime Therapeutics Inc. (South San Francisco, Calif.); iTherX Pharmaceuticals Inc....
BioCentury | Oct 24, 2011
Finance

Highlights of weekly biotech stock moves

...royalty bearing asset acquisition opportunities. Berger is a director at: Five Prime Therapeutics Inc. ; iTherX Pharmaceuticals Inc....
BioCentury | May 12, 2011
Cover Story

Making the most of the host

...at the University of California, San Diego and EVP and CSO of infectious disease company iTherX Pharmaceuticals Inc....
...most advanced. The pharma's other compound is NIM811 , which is in Phase II studies. iTherX's...
...Paris, France Institut National de la Santé et de la Recherche Médicale , Strasbourg, France iTherX Pharmaceuticals Inc....
BioCentury | Mar 21, 2011
Clinical News

ITX 5061: Phase Ib started

...5061 plus supportive care vs. supportive care alone in about 20 patients for 7 days. iTherX Pharmaceuticals Inc....
BioCentury | Sep 23, 2010
Distillery Therapeutics

Indication: Inflammation

...the inhibitors in chimeric mice with human livers. ITX5061, a small molecule entry inhibitor from iTherX Pharmaceuticals Inc....
BioCentury | Feb 4, 2010
Targets & Mechanisms

Blocking and watching HCV

...at the University of California, San Diego and EVP and CSO of infectious disease company ItherX Pharmaceuticals Inc....
...order to optimize compounds for metabolic stability, enzymatic clearance and hepatotoxicity in human target cells." ItherX's...
...and Institutions Mentioned Eiger Biopharmaceuticals Inc. , Palo Alto, Calif. Hepregen Corp. , Medford, Mass. ItherX Pharmaceuticals Inc....
BioCentury | Feb 9, 2009
Clinical News

ITX5061: Phase IIa start

...Next month, iTherX will begin a double-blind, placebo-controlled, European Phase IIa trial to evaluate oral ITX5061...
...Phase IIa trial to evaluate oral ITX5061 as a single agent in about 40 patients. iTherX Pharmaceuticals Inc....
BioCentury | Dec 24, 2007
Company News

iTherX management update

ItherX Pharmaceuticals Inc. , San Diego, Calif. Business: Cancer, Infectious Hired: Jeffrey McKelvy as president, CEO and a director, formerly CEO of Avera Pharmaceuticals Inc. ; he succeeds Tsvi Goldenberg, who will remain chairman WIR Staff...
BioCentury | Apr 10, 2006
Company News

BioInvent, Immusol deal

...preclinical antibody to treat age-related macular degeneration (AMD). BINV will provide the human antibody, and Immusol...
...target. The companies will share costs and potential revenues. BioInvent International AB (SSE:BINV), Lund, Sweden Immusol...
BioCentury | Feb 6, 2006
Company News

Immusol, Baylor College of Medicine deal

...Baylor granted Immusol an exclusive worldwide license to a preclinical oncolytic viral therapy to treat solid...
...a preclinical oncolytic viral therapy to treat solid tumors. The therapy uses herpes simplex viruses. Immusol...
Items per page:
1 - 10 of 50
BioCentury | Oct 24, 2011
Company News

PDL BioPharma other news

...acquisition opportunities. Berger is a director at: Five Prime Therapeutics Inc. (South San Francisco, Calif.); iTherX Pharmaceuticals Inc....
BioCentury | Oct 24, 2011
Finance

Highlights of weekly biotech stock moves

...royalty bearing asset acquisition opportunities. Berger is a director at: Five Prime Therapeutics Inc. ; iTherX Pharmaceuticals Inc....
BioCentury | May 12, 2011
Cover Story

Making the most of the host

...at the University of California, San Diego and EVP and CSO of infectious disease company iTherX Pharmaceuticals Inc....
...most advanced. The pharma's other compound is NIM811 , which is in Phase II studies. iTherX's...
...Paris, France Institut National de la Santé et de la Recherche Médicale , Strasbourg, France iTherX Pharmaceuticals Inc....
BioCentury | Mar 21, 2011
Clinical News

ITX 5061: Phase Ib started

...5061 plus supportive care vs. supportive care alone in about 20 patients for 7 days. iTherX Pharmaceuticals Inc....
BioCentury | Sep 23, 2010
Distillery Therapeutics

Indication: Inflammation

...the inhibitors in chimeric mice with human livers. ITX5061, a small molecule entry inhibitor from iTherX Pharmaceuticals Inc....
BioCentury | Feb 4, 2010
Targets & Mechanisms

Blocking and watching HCV

...at the University of California, San Diego and EVP and CSO of infectious disease company ItherX Pharmaceuticals Inc....
...order to optimize compounds for metabolic stability, enzymatic clearance and hepatotoxicity in human target cells." ItherX's...
...and Institutions Mentioned Eiger Biopharmaceuticals Inc. , Palo Alto, Calif. Hepregen Corp. , Medford, Mass. ItherX Pharmaceuticals Inc....
BioCentury | Feb 9, 2009
Clinical News

ITX5061: Phase IIa start

...Next month, iTherX will begin a double-blind, placebo-controlled, European Phase IIa trial to evaluate oral ITX5061...
...Phase IIa trial to evaluate oral ITX5061 as a single agent in about 40 patients. iTherX Pharmaceuticals Inc....
BioCentury | Dec 24, 2007
Company News

iTherX management update

ItherX Pharmaceuticals Inc. , San Diego, Calif. Business: Cancer, Infectious Hired: Jeffrey McKelvy as president, CEO and a director, formerly CEO of Avera Pharmaceuticals Inc. ; he succeeds Tsvi Goldenberg, who will remain chairman WIR Staff...
BioCentury | Apr 10, 2006
Company News

BioInvent, Immusol deal

...preclinical antibody to treat age-related macular degeneration (AMD). BINV will provide the human antibody, and Immusol...
...target. The companies will share costs and potential revenues. BioInvent International AB (SSE:BINV), Lund, Sweden Immusol...
BioCentury | Feb 6, 2006
Company News

Immusol, Baylor College of Medicine deal

...Baylor granted Immusol an exclusive worldwide license to a preclinical oncolytic viral therapy to treat solid...
...a preclinical oncolytic viral therapy to treat solid tumors. The therapy uses herpes simplex viruses. Immusol...
Items per page:
1 - 10 of 50